News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
731,545 Results
Type
Article (41398)
Company Profile (310)
Press Release (689825)
Multimedia
Podcasts (82)
Webinars (18)
Section
Business (207111)
Career Advice (2039)
Deals (35857)
Drug Delivery (114)
Drug Development (82482)
Employer Resources (175)
FDA (16476)
Job Trends (15088)
News (350366)
Policy (32946)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2581)
Accelerated approval (38)
Adcomms (24)
Allergies (152)
Alliances (50232)
ALS (178)
Alzheimer's disease (1689)
Antibody-drug conjugate (ADC) (332)
Approvals (16769)
Artificial intelligence (548)
Autoimmune disease (175)
Automation (46)
Bankruptcy (361)
Best Places to Work (11737)
BIOSECURE Act (20)
Biosimilars (198)
Biotechnology (205)
Bladder cancer (168)
Brain cancer (60)
Breast cancer (656)
Cancer (5018)
Cardiovascular disease (427)
Career advice (1723)
Career pathing (37)
CAR-T (288)
CDC (50)
Celiac Disease (2)
Cell therapy (769)
Cervical cancer (38)
Clinical research (70695)
Collaboration (1797)
Company closure (4)
Compensation (1208)
Complete response letters (60)
COVID-19 (2728)
CRISPR (98)
C-suite (907)
Cystic fibrosis (147)
Data (6524)
Decentralized trials (2)
Denatured (25)
Depression (141)
Diabetes (513)
Diagnostics (6765)
Digital health (49)
Diversity (12)
Diversity, equity & inclusion (45)
Drug discovery (264)
Drug pricing (187)
Drug shortages (28)
Duchenne muscular dystrophy (240)
Earnings (91486)
Editorial (59)
Employer branding (22)
Employer resources (154)
Events (120015)
Executive appointments (1010)
FDA (19709)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (25)
Funding (1526)
Gene editing (207)
Generative AI (44)
Gene therapy (621)
GLP-1 (992)
Government (4693)
Grass and pollen (7)
Guidances (385)
Healthcare (18942)
HIV (69)
Huntington's disease (48)
IgA nephropathy (85)
Immunology and inflammation (257)
Immuno-oncology (66)
Indications (134)
Infectious disease (3012)
Inflammatory bowel disease (196)
Inflation Reduction Act (14)
Influenza (123)
Intellectual property (259)
Interviews (320)
IPO (16835)
IRA (50)
Job creations (3690)
Job search strategy (1438)
JPM (58)
Kidney cancer (18)
Labor market (88)
Layoffs (552)
Leadership (33)
Legal (7978)
Liver cancer (94)
Longevity (19)
Lung cancer (673)
Lymphoma (387)
Machine learning (46)
Management (59)
Manufacturing (838)
MASH (170)
Medical device (13811)
Medtech (13873)
Mergers & acquisitions (20133)
Metabolic disorders (1309)
mRNA (159)
Multiple sclerosis (172)
NASH (16)
Neurodegenerative disease (337)
Neuropsychiatric disorders (89)
Neuroscience (2984)
Neurotech (1)
NextGen: Class of 2026 (6546)
Non-profit (4534)
Now hiring (69)
Obesity (615)
Opinion (268)
Ovarian cancer (171)
Pain (212)
Pancreatic cancer (239)
Parkinson's disease (293)
Partnered (33)
Patents (520)
Patient recruitment (536)
Peanut (60)
People (59722)
Pharmaceutical (73)
Pharmacy benefit managers (30)
Phase 1 (22066)
Phase 2 (31162)
Phase 3 (23104)
Pipeline (5959)
Policy (294)
Postmarket research (2570)
Preclinical (9357)
Press Release (64)
Prostate cancer (256)
Psychedelics (48)
Radiopharmaceuticals (300)
Rare diseases (905)
Real estate (6049)
Recruiting (71)
Regulatory (24849)
Reports (53)
Research institute (2411)
Resumes & cover letters (353)
Rett syndrome (30)
RNA editing (16)
RSV (81)
Schizophrenia (152)
Series A (252)
Series B (193)
Service/supplier (11)
Sickle cell disease (101)
Special edition (22)
Spinal muscular atrophy (158)
Sponsored (42)
Startups (3664)
State (2)
Stomach cancer (18)
Supply chain (107)
Tariffs (84)
The Weekly (55)
Vaccines (1028)
Venture capital (93)
Weight loss (391)
Women's health (99)
Worklife (19)
Date
Today (157)
Last 7 days (825)
Last 30 days (3011)
Last 365 days (30228)
2026 (5305)
2025 (30429)
2024 (35562)
2023 (40473)
2022 (51633)
2021 (56245)
2020 (54472)
2019 (46906)
2018 (35318)
2017 (32508)
2016 (31952)
2015 (38017)
2014 (31844)
2013 (26768)
2012 (28943)
2011 (29608)
2010 (27675)
Location
Africa (746)
Alabama (91)
Alaska (7)
Arizona (318)
Arkansas (14)
Asia (40285)
Australia (6538)
California (11735)
Canada (3379)
China (1164)
Colorado (495)
Connecticut (500)
Delaware (345)
Europe (87647)
Florida (1780)
Georgia (374)
Hawaii (3)
Idaho (61)
Illinois (901)
India (73)
Indiana (540)
Iowa (22)
Japan (453)
Kansas (127)
Kentucky (43)
Louisiana (31)
Maine (72)
Maryland (1434)
Massachusetts (8459)
Michigan (337)
Minnesota (641)
Mississippi (6)
Missouri (131)
Montana (32)
Nebraska (29)
Nevada (127)
New Hampshire (80)
New Jersey (3130)
New Mexico (29)
New York (3101)
North Carolina (1557)
North Dakota (8)
Northern California (5762)
Ohio (348)
Oklahoma (21)
Oregon (42)
Pennsylvania (2361)
Puerto Rico (25)
Rhode Island (49)
South America (1121)
South Carolina (68)
South Dakota (1)
Southern California (4582)
Tennessee (186)
Texas (1808)
United States (41724)
Utah (351)
Vermont (1)
Virginia (277)
Washington D.C. (81)
Washington State (957)
West Virginia (4)
Wisconsin (115)
Wyoming (2)
731,545 Results for "tlc biopharmaceuticals inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
OrsoBio Announces Positive Topline Phase 2a Data for LXR Inverse Agonist TLC-2716 in Severe Hypertriglyceridemia and Metabolic Liver Disease
February 10, 2026
·
3 min read
Press Releases
OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases
January 16, 2026
·
4 min read
Press Releases
OrsoBio Announces Positive Topline Phase 1b/2a Clinical Data for its Oral Mitochondrial Protonophore TLC-6740 in Combination with Tirzepatide
December 17, 2025
·
5 min read
Press Releases
SPEAR Study Group to Present its Recommended Long COVID Antibody Study Design Featuring Invivyd’s VYD2311 At RECOVER-TLC Workshop September 9-10, 2025
September 4, 2025
·
8 min read
Press Releases
Sparrow Appoints Biopharmaceutical Industry Veteran, Carlo Incerti, M.D. to its Board of Directors
February 2, 2026
·
3 min read
Biotech Bay
OrsoBio to Present Phase 1 and Preclinical Data for Liver-Targeted Mitochondrial Protonophore TLC-6740 at the American Diabetes Association’s 84th Scientific Sessions
OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for obesity and obesity-associated disorders, today announced new data for liver-targeted mitochondrial protonophore TLC-6740 being presented at the 84th Scientific Sessions of the American Diabetes Association being held June 21-24, 2024, in Orlando, Fla.
June 21, 2024
·
6 min read
Drug Development
TLC to Present Phase 3 Data of TLC599 in Late-Breaking Abstracts Session at ACR
TLC BioSciences announced that the Abstract Selection Committee of the American College of Rheumatology has accepted TLC’s late-breaking abstract on TLC599 for oral presentation at ACR Convergence 2023.
November 8, 2023
·
4 min read
Press Releases
Angitia Biopharmaceuticals Announces $130 Million Series D Financing
February 5, 2026
·
4 min read
Press Releases
AsymBio Establishes Integrated Technology Platforms Spanning the Full Biopharmaceutical Development Lifecycle
February 11, 2026
·
4 min read
Drug Development
OrsoBio to Present Phase 1 Data for the Liver-Targeted Mitochondrial Protonophore TLC-6740 in Development for the Treatment of Obesity at ObesityWeek® 2023
OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced preliminary safety and pharmacokinetic (PK) data from the single ascending dose (SAD) portion of an ongoing Phase 1 trial of TLC-6740, a liver-targeted, mitochondrial protonophore.
October 16, 2023
·
5 min read
1 of 73,155
Next
